Basic Information
VistaGen is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with central nervous system (CNS) diseases and conditions. VistaGen's lead candidate, AV-101, is a next-generation, Phase 2 oral prodrug candidate.
VistaGen Therapeutics, Inc.
SanFrancisco,California,United States of America
15~50 people
January 01, 1998
Investor.relations@vistagen.com